Found 167 articles for: "Psoriasis"
Testing the article for PII
March 2025 | Volume 24 | Issue 3 | Supplement | 5644 | Copyright © March 2025
Test...
Read MoreStructural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis
October 2024 | Volume 23 | Issue 10 | Features | 903 | Copyright © October 2024
Read MoreSelective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 645 | Copyright © August 2024
Members of the Janus kinase (JAK) superfamily, comprising tyrosine kinase 2 (TYK2) and JAK1, JAK2, and JAK3, mediate signaling by cytokines (eg, interleukin [IL]-23) involved in psoriasis pathoge...
Read MoreTildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 612 | Copyright © August 2024
Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real-world effectiveness a...
Read MoreSafety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
August 2024 | Volume 23 | Issue 8 | Original Article | 592 | Copyright © August 2024
Background: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target bot...
Read MoreBenefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
August 2024 | Volume 23 | Issue 8 | Original Article | 619 | Copyright © August 2024
Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outco...
Read MoreEfficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI
August 2024 | Volume 23 | Issue 8 | Original Article | 600 | Copyright © August 2024
Background: There is a paucity of data on the treatment of psoriasis in patients with skin of color – a diverse population among whom variations in clinical features and hi...
Read MoreThe Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis: A Retrospective, Multicenter, Observational Study
August 2024 | Volume 23 | Issue 8 | Editorials | e169 | Copyright © August 2024
Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 607 | Copyright © August 2024
Background: The combined use of topical calcipotriol/betamethasone dipropionate (Cal/BDP) is commonly used and demonstrated to be effective for the management of psoriasis and is...
Read MoreThe Hidden Costs of Psoriasis: A Population-Based Study Evaluating How Psoriasis Severity Impacts Work Absenteeism
August 2024 | Volume 23 | Issue 8 | Original Article | 640 | Copyright © August 2024
Background: Psoriasis patients experience physical and emotional burdens, which may lead to work-related productivity loss. This loss carries professional and financial repercuss...
Read MoreReal-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study
August 2024 | Volume 23 | Issue 8 | Original Article | 632 | Copyright © August 2024
Background: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-...
Read MoreRapid Remission of Plaque Psoriasis With Bimekizumab Treatment
August 2024 | Volume 23 | Issue 8 | Features | 694 | Copyright © August 2024
Bimekizumab is a novel humanized bispecific monoclonal immunoglobulin G1 (IgG1) antibody that dually inhibits both IL-17A and IL-17F. Investigation of the pivotal role of IL-17A, and more recentl...
Read MoreThe Treatment of Psoriasis With Intramuscular Triamcinolone
August 2024 | Volume 23 | Issue 8 | Features | 688 | Copyright © August 2024
Recalcitrant Erythrodermic Psoriasis Complicated by Septic Shock and Mycotic Aneurysm: A Call for Treatment Guidelines
August 2024 | Volume 23 | Issue 8 | Case Reports | 680 | Copyright © August 2024
Erythroderma is characterized by diffuse erythema and scale covering over 90% body surface area that can affect individuals with inflammatory dermatoses such as psoriasis. Complications of erythr...
Read MoreFirst Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis
March 2024 | Volume 23 | Issue 3 | Case Reports | 192 | Copyright © March 2024
Plaque psoriasis is a chronic, immune-mediated, cutaneous, and systemic inflammatory dermatosis. Its pathogenesis involves the dysregulation of the interleukin (IL)-23/IL-17 signaling pathway. Th...
Read MoreHalobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 50 | Copyright © February 2024
Introduction: Moisturizers are often used as adjuvant therapy for psoriasis to assist with rehydration and skin barrier restoration. Fixed-combination halobetasol propionate 0.01...
Read MoreImplicit Bias and Clinical Decision Making in Psoriasis Management Among Dermatology Residents: A Feasibility Study
February 2024 | Volume 23 | Issue 2 | Editorials | e73 | Copyright © February 2024
Tips, Trends, and Truths: A Study of Psoriasis Treatment Content on TikTok
February 2024 | Volume 23 | Issue 2 | Editorials | e67 | Copyright © February 2024
Introduction: With more than two billion downloads since its launch, TikTok is the fastest-growing video-sharing platform in the world. Many people turn to TikTok for dermat...
Read MorePsoriasis and Palmoplantar Pustulosis Following Pembrolizumab Therapy Successfully Treated With Topical Tapinarof Cream 1%
February 2024 | Volume 23 | Issue 2 | Case Reports | 103 | Copyright © February 2024
Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
